Prelude Therapeutics Collaborates With Merck To Evaluate PRT3789 Combined With KEYTRUDA (Pembrolizumab) In Patients With SMARCA4-Mutated Cancers

7/9/24 7:34:54 AM ET

$MRK

$PRLD

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MRK alert in real time by email

Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the two mechanisms.

Prelude will sponsor the clinical trial and Merck will provide KEYTRUDA.

Get the next $MRK alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MRK
$PRLD

Company	Date	Price Target	Rating	Analyst
Merck & Company Inc. $MRK	11/15/2024		Peer Perform	Wolfe Research
Merck & Company Inc. $MRK	11/11/2024		Buy → Neutral	Daiwa Securities
Merck & Company Inc. $MRK	10/17/2024	$115.00	Mkt Perform	Bernstein
Prelude Therapeutics Incorporated $PRLD	9/19/2024	$5.00	Neutral → Buy	H.C. Wainwright
Prelude Therapeutics Incorporated $PRLD	6/20/2024	$3.00	Equal Weight → Underweight	Barclays
Prelude Therapeutics Incorporated $PRLD	3/13/2024	$7.00	Mkt Outperform	JMP Securities
Merck & Company Inc. $MRK	3/11/2024	$104.00	Hold → Sell	Societe Generale
Prelude Therapeutics Incorporated $PRLD	2/20/2024	$5.00	Buy → Neutral	H.C. Wainwright

More analyst ratings

$MRK
$PRLD
Press Releases

Fastest customizable press release news feed in the world

Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories, is scheduled to participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 1:20 p.m. EST. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at this weblink. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives
11/22/24 7:15:00 AM ET
$MRK
Biotechnology: Pharmaceutical Preparations
Health Care
Merck's WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
WELIREG is the first and only systemic therapy approved in China for adult patients with certain VHL disease-associated tumors Decision marks first approval for WELIREG in China and 17th approval of WELIREG for these patients globally Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the National Medical Products Administration (NMPA) in China has approved WELIREG® (belzutifan), for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. WELIREG is
11/22/24 6:45:00 AM ET
$MRK
Biotechnology: Pharmaceutical Preparations
Health Care
Surendralal Karsanbhai Elected to Merck Board of Directors
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that Surendralal L. "Lal" Karsanbhai, president and chief executive officer, Emerson Electric Co. (NYSE:EMR), will join Merck's board of directors effective January 1, 2025. He will stand for election by the company's shareholders in May 2025. With the addition of Mr. Karsanbhai, the Merck board will consist of 13 members. "We are pleased to welcome Lal Karsanbhai to the Merck board. Lal brings extensive business and operational expertise with a strong global perspective, and we look forward to his contributions and insights," said Robert M. Davis, chairman and chief executive officer, Merck. Mr. Kar
11/22/24 6:30:00 AM ET
$EMR
$MRK
Consumer Electronics/Appliances
Technology
Biotechnology: Pharmaceutical Preparations
Health Care

Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023
WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023. Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua
11/14/23 5:25:00 PM ET
$ASH
$MRK
Specialty Chemicals
Consumer Discretionary
Biotechnology: Pharmaceutical Preparations
Health Care
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver
5/18/23 8:00:00 AM ET
$ALLO
$AMGN
$MRK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update
Prelude remains on track for clinical data readouts and next steps for the PRMT5 program, MCL1 inhibitor PRT1419, and CDK9 inhibitor PRT2527 in 2H2022 Strong cash and cash equivalents of $266.2 million as of March 31, 2022, expected to fund operations into 2H2024 WILMINGTON, Del., May 10, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated ("Prelude") (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022, and provided an update on recent clinical and development pipeline progress. "Prelude continues to make great progress in discovering and advancing a diverse pipeline of differentiated small molecu
5/10/22 8:00:00 AM ET
$PRLD
Biotechnology: Pharmaceutical Preparations
Health Care

Merck Announces First-Quarter 2025 Dividend
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the first quarter of 2025. Payment will be made on Jan. 8, 2025, to shareholders of record at the close of business on Dec. 16, 2024. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intens
11/19/24 12:22:00 PM ET
$MRK
Biotechnology: Pharmaceutical Preparations
Health Care
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
11/7/24 7:00:00 AM ET
$AGEN
$LGND
$MRK
$TAK
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Merck Announces Third-Quarter 2024 Financial Results
Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 7% KEYTRUDA Sales Grew 17% to $7.4 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 21% WINREVAIR Sales Were $149 Million; U.S. Launch of WINREVAIR Gaining Momentum; Received Approval in the EU Animal Health Sales Grew 6% to $1.5 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 11% GAAP EPS Was $1.24; Non-GAAP EPS Was $1.57; GAAP and Non-GAAP EPS Include a Net Charge of $0.79 per Share Related to Certain Business Development Transactions Achieved Significant Milestones in Vaccine Programs CAPVAXIVE Recommended by t
10/31/24 6:30:00 AM ET
$MRK
Biotechnology: Pharmaceutical Preparations
Health Care

Prelude Therapeutics Collaborates With Merck To Evaluate PRT3789 Combined With KEYTRUDA (Pembrolizumab) In Patients With SMARCA4-Mutated Cancers

Chat with this insight

Recent Analyst Ratings for $MRK$PRLD

$MRK$PRLD Press Releases

Fastest customizable press release news feed in the world

Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Merck's WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors

Surendralal Karsanbhai Elected to Merck Board of Directors

$MRK$PRLD SEC Filings

SEC Form 10-Q filed by Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Merck & Company Inc.

$MRK$PRLD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$MRK$PRLD Leadership Updates

Live Leadership Updates

$MRK$PRLD Large Ownership Changes

This live feed shows all institutional transactions in real time.

$MRK$PRLD Financials

Live finance-specific insights

$MRK$PRLD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Wolfe Research initiated coverage on Merck

Merck downgraded by Daiwa Securities

Bernstein initiated coverage on Merck with a new price target

Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

SEC Form SC 13G/A filed by Merck & Company Inc. (Amendment)

SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

Merck Announces First-Quarter 2025 Dividend

Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance

Merck Announces Third-Quarter 2024 Financial Results

SEC Form 4 filed by Director Seidman Christine E

SEC Form 4 filed by Director Glocer Thomas H

SEC Form 4 filed by Director Coe Mary Ellen

$MRK$PRLD Market Insights

Live Market Insights

Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants

Merck Says Its Prophylactic Monoclonal Antibody Clesrovimab For Respiratory Syncytial Virus (RSV) Disease Met Its Primary Safety And Efficacy Endpoints

Merck Reports Results From Phase 2b/3 Trial Of Clesrovimab Antibody Designed To Protect Infants From Respiratory Syncytial Virus Disease; Says Clesrovimab Met All Primary Safety And Efficacy Endpoints

Recent Analyst Ratings for
$MRK
$PRLD

$MRK
$PRLD
Press Releases

$MRK
$PRLD
SEC Filings

$MRK
$PRLD
Analyst Ratings

$MRK
$PRLD
Leadership Updates

$MRK
$PRLD
Large Ownership Changes

$MRK
$PRLD
Financials

$MRK
$PRLD
Insider Trading

$MRK
$PRLD
Market Insights